{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T04:26:26Z","timestamp":1794457586633,"version":"4.9.1"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Cannabis legalization for medical and recreational purposes has been suggested as an effective strategy to reduce opioid and benzodiazepine use and deaths. We examined the county-level association between medical and recreational cannabis laws and poisoning deaths involving opioids and benzodiazepines in the US from 2002 to 2020.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Our ecologic county-level, spatiotemporal study comprised 49 states. Exposures were state-level implementation of medical and recreational cannabis laws and state-level initiation of cannabis dispensary sales. Our main outcomes were poisoning deaths involving any opioid, any benzodiazepine, and opioids with benzodiazepines. Secondary analyses included overdoses involving natural and semi-synthetic opioids, synthetic opioids, and heroin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Implementation of medical cannabis laws was associated with increased deaths involving opioids (rate ratio [RR] = 1.14; 95% credible interval [CrI] = 1.11, 1.18), benzodiazepines (RR = 1.19; 95% CrI = 1.12, 1.26), and opioids+benzodiazepines (RR = 1.22; 95% CrI = 1.15, 1.30). Medical cannabis legalizations allowing dispensaries was associated with fewer deaths involving opioids (RR = 0.88; 95% CrI = 0.85, 0.91) but not benzodiazepine deaths; results for recreational cannabis implementation and opioid deaths were similar (RR = 0.81; 95% CrI = 0.75, 0.88). Recreational cannabis laws allowing dispensary sales was associated with consistent reductions in opioid- (RR = 0.83; 95% CrI = 0.76, 0.91), benzodiazepine- (RR = 0.79; 95% CrI = 0.68, 0.92), and opioid+benzodiazepine-related poisonings (RR = 0.83; 95% CrI = 0.70, 0.98).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Implementation of medical cannabis laws was associated with higher rates of opioid- and benzodiazepine-related deaths, whereas laws permitting broader cannabis access, including implementation of recreational cannabis laws and medical and recreational dispensaries, were associated with lower rates. The estimated effects of the expanded availability of cannabis seem dependent on the type of law implemented and its provisions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ede.0000000000001609","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T14:01:26Z","timestamp":1679407286000},"page":"467-475","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Changes in Opioid and Benzodiazepine Poisoning Deaths After Cannabis Legalization in the US: A County-level Analysis, 2002\u20132020"],"prefix":"10.1097","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3016-890X","authenticated-orcid":false,"given":"Alvaro","family":"Castillo-Carniglia","sequence":"first","affiliation":[{"name":"Society and Health Research Center and School of Public Health, Facultad de Ciencias Sociales y Artes, Universidad Mayor, Chile"},{"name":"Millennium Nucleus for the Evaluation and Analysis of Drug Policies (nDP), Chile"},{"name":"Millennium Nucleus on Sociomedicine (Sociomed), Chile"},{"name":"Department of Population Health, New York University Grossman School of Medicine, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadne","family":"Rivera-Aguirre","sequence":"additional","affiliation":[{"name":"Millennium Nucleus for the Evaluation and Analysis of Drug Policies (nDP), Chile"},{"name":"Department of Population Health, New York University Grossman School of Medicine, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Santaella-Tenorio","sequence":"additional","affiliation":[{"name":"Department of Population Health, New York University Grossman School of Medicine, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Fink","sequence":"additional","affiliation":[{"name":"New York State Psychiatric Institute, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Crystal","sequence":"additional","affiliation":[{"name":"Center for Health Services Research, Institute for Health, Rutgers University, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Ponicki","sequence":"additional","affiliation":[{"name":"Prevention Research Center, Pacific Institute for Research and Evaluation, Berkeley, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gruenewald","sequence":"additional","affiliation":[{"name":"Prevention Research Center, Pacific Institute for Research and Evaluation, Berkeley, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia S.","family":"Martins","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Columbia University, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Keyes","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Columbia University, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Cerd\u00e1","sequence":"additional","affiliation":[{"name":"Department of Population Health, New York University Grossman School of Medicine, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"R3-20250801","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.drugalcdep.2012.07.004","article-title":"Polydrug abuse: a review of opioid and benzodiazepine combination use.","volume":"125","author":"Jones","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"R4-20250801","first-page":"85","article-title":"Cohort study of the impact of high-dose opioid analgesics on overdose mortality.","volume":"17","author":"Dasgupta","year":"2016","journal-title":"Pain Med"},{"key":"R5-20250801","doi-asserted-by":"crossref","first-page":"e198325","DOI":"10.1001\/jamanetworkopen.2019.8325","article-title":"Rates of physician coprescribing of opioids and benzodiazepines after the release of the centers for disease control and prevention guidelines in 2016.","volume":"2","author":"Jeffery","year":"2019","journal-title":"JAMA Netw Open"},{"key":"R6-20250801","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drugpo.2017.01.011","article-title":"Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients.","volume":"42","author":"Lucas","year":"2017","journal-title":"Int J Drug Policy"},{"key":"R7-20250801","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/02791072.2011.587700","article-title":"Who are medical marijuana patients? Population characteristics from nine California assessment clinics.","volume":"43","author":"Reinarman","year":"2011","journal-title":"J Psychoactive Drugs"},{"key":"R8-20250801","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12954-017-0183-9","article-title":"Rationale for cannabis-based interventions in the opioid overdose crisis.","volume":"14","author":"Lucas","year":"2017","journal-title":"Harm Reduct J"},{"key":"R9-20250801","doi-asserted-by":"crossref","first-page":"j760","DOI":"10.1136\/bmj.j760","article-title":"Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis.","volume":"356","author":"Sun","year":"2017","journal-title":"BMJ"},{"key":"R10-20250801","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14737167.2020.1807944","article-title":"In our war against the opioid epidemic, could \u201cweed\u201d be a winner?.","volume":"20","author":"Ding","year":"2020","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"R11-20250801","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drugalcdep.2018.09.016","article-title":"Recreational marijuana legalization and prescription opioids received by Medicaid enrollees.","volume":"194","author":"Shi","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"R12-20250801","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40621-019-0213-z","article-title":"State marijuana laws and opioid overdose mortality.","volume":"6","author":"Chihuri","year":"2019","journal-title":"Inj Epidemiol"},{"key":"R13-20250801","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.outlook.2017.08.012","article-title":"The use of cannabis in response to the opioid crisis: a review of the literature.","volume":"66","author":"Vyas","year":"2018","journal-title":"Nurs Outlook"},{"key":"R16-20250801","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2105\/AJPH.2016.303061","article-title":"Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013.","volume":"106","author":"Bachhuber","year":"2016","journal-title":"Am J Public Health"},{"key":"R17-20250801","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.2013.272","article-title":"Pharmaceutical overdose deaths, United States, 2010.","volume":"309","author":"Jones","year":"2013","journal-title":"JAMA"},{"key":"R18-20250801","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1093\/aje\/kwab192","article-title":"Spatiotemporal analysis of the association between pain management clinic laws and opioid prescribing and overdose deaths.","volume":"190","author":"Cerda","year":"2021","journal-title":"Am J Epidemiol"},{"key":"R20-20250801","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1146\/annurev-clinpsy-032816-045128","article-title":"Medical marijuana and marijuana legalization.","volume":"13","author":"Pacula","year":"2017","journal-title":"Annu Rev Clin Psychol"},{"key":"R21-20250801","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jhealeco.2017.12.007","article-title":"Do medical marijuana laws reduce addictions and deaths related to pain killers?","volume":"58","author":"Powell","year":"2018","journal-title":"J Health Econ"},{"key":"R22-20250801","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/EDE.0000000000001123","article-title":"Measuring relationships between proactive reporting state-level prescription drug monitoring programs and county-level fatal prescription opioid overdoses.","volume":"31","author":"Cerda","year":"2020","journal-title":"Epidemiology"},{"key":"R25-20250801","doi-asserted-by":"crossref","first-page":"e1919066","DOI":"10.1001\/jamanetworkopen.2019.19066","article-title":"Association of medicaid expansion with opioid overdose mortality in the United States.","volume":"3","author":"Kravitz-Wirtz","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R26-20250801","doi-asserted-by":"crossref","first-page":"e2036687","DOI":"10.1001\/jamanetworkopen.2020.36687","article-title":"Systematic evaluation of state policy interventions targeting the US opioid epidemic, 2007-2018.","volume":"4","author":"Lee","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R27-20250801","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.addbeh.2018.03.014","article-title":"Opioid-overdose laws association with opioid use and overdose mortality.","volume":"86","author":"McClellan","year":"2018","journal-title":"Addict Behav"},{"key":"R28-20250801","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.drugpo.2019.10.001","article-title":"Prescription drug monitoring programs operational characteristics and fatal heroin poisoning.","volume":"74","author":"Martins","year":"2019","journal-title":"Int J Drug Policy"},{"key":"R29-20250801","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/EDE.0000000000000950","article-title":"Prescription drug monitoring programs and opioid overdoses: exploring sources of heterogeneity.","volume":"30","author":"Castillo-Carniglia","year":"2019","journal-title":"Epidemiology"},{"key":"R33-20250801","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1002\/1097-0258(20000915\/30)19:17\/18<2555::AID-SIM587>3.0.CO;2-#","article-title":"Bayesian modelling of inseparable space\u2013time variation in disease risk.","volume":"19","author":"Knorr-Held","year":"2000","journal-title":"Stat Med"},{"key":"R34-20250801","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1002\/sim.4780142112","article-title":"Bayesian analysis of space\u2013time variation in disease risk.","volume":"14","author":"Bernardinelli","year":"1995","journal-title":"Stat Med"},{"key":"R36-20250801","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.aap.2004.02.004","article-title":"Poisson, Poisson-gamma and zero-inflated regression models of motor vehicle crashes: balancing statistical fit and theory.","volume":"37","author":"Lord","year":"2005","journal-title":"Accid Anal Prev"},{"key":"R38-20250801","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.sste.2012.12.001","article-title":"Spatial and spatio-temporal models with R-INLA.","volume":"4","author":"Blangiardo","year":"2013","journal-title":"Spat Spatiotemporal Epidemiol"},{"key":"R39-20250801","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/rssb.12062","article-title":"The Deviance Information Criterion: 12 Years on.","volume":"76","author":"Spiegelhalter","year":"2014","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"R40-20250801","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1001\/jamapsychiatry.2017.0724","article-title":"US adult illicit cannabis use, cannabis use disorder, and medical marijuana laws: 1991-1992 to 2012-2013.","volume":"74","author":"Hasin","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"R41-20250801","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/add.15031","article-title":"Medical marijuana laws and driving under the influence of marijuana and alcohol.","volume":"115","author":"Fink","year":"2020","journal-title":"Addiction"},{"key":"R42-20250801","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/injuryprev-2020-043830","article-title":"Overcoming the limitations of \u201caccident\u201d as a manner of death for drug overdose mortality: case for a death certificate checkbox.","volume":"27","author":"Rockett","year":"2021","journal-title":"Inj Prev"},{"key":"R43-20250801","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/env.1065","article-title":"Spatio-temporal disease mapping using INLA.","volume":"22","author":"Schrodle","year":"2011","journal-title":"Environmetrics"},{"key":"R44-20250801","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/0962280214527528","article-title":"On fitting spatio-temporal disease mapping models using approximate Bayesian inference.","volume":"23","author":"Ugarte","year":"2014","journal-title":"Stat Methods Med Res"},{"key":"R45-20250801","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1467-9868.2008.00700.x","article-title":"Approximate Bayesian inference for latent Gaussian models using integrated nested Laplace approximations (with discussion).","volume":"71","author":"Rue","year":"2009","journal-title":"J R Stat Soc Series B"},{"key":"R47-20250801","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5055\/jom.2017.0391","article-title":"Implications of prescription drug monitoring and medical cannabis legislation on opioid overdose mortality.","volume":"13","author":"Phillips","year":"2017","journal-title":"J Opioid Manag"},{"key":"R48-20250801","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1073\/pnas.1903434116","article-title":"Association between medical cannabis laws and opioid overdose mortality has reversed over time.","volume":"116","author":"Shover","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R49-20250801","first-page":"347","article-title":"Medical marijuana laws and their effect on opioid related mortality.","volume":"39","author":"Averett","year":"2019","journal-title":"Econ Bulletin"},{"key":"R50-20250801","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/ecin.12819","article-title":"The effects of recreational marijuana legalization and dispensing on opioid mortality.","volume":"58","author":"Chan","year":"2020","journal-title":"Econ Inquiry"},{"key":"R51-20250801","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/add.13741","article-title":"Do more robust prescription drug monitoring programs reduce prescription opioid overdose?.","volume":"112","author":"Pardo","year":"2017","journal-title":"Addiction"},{"key":"R52-20250801","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/ecin.12825","article-title":"The effects of medical marijuana dispensaries on adverse opioid outcomes.","volume":"58","author":"Smith","year":"2020","journal-title":"Econ Inquiry"},{"key":"R53-20250801","doi-asserted-by":"crossref","first-page":"m4957","DOI":"10.1136\/bmj.m4957","article-title":"Association between county level cannabis dispensary counts and opioid related mortality rates in the United States: panel data study.","volume":"372","author":"Hsu","year":"2021","journal-title":"BMJ"},{"key":"R54-20250801","doi-asserted-by":"crossref","first-page":"102728","DOI":"10.1016\/j.jhealeco.2023.102728","article-title":"Marijuana legalization and opioid deaths.","volume":"88","author":"Mathur","year":"2023","journal-title":"J Health Econ"},{"key":"R55-20250801","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/add.14238","article-title":"Cannabis and opioid overdoses: time to move on and examine potential mechanisms.","volume":"113","author":"Rogeberg","year":"2018","journal-title":"Addiction"},{"key":"R56-20250801","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6901a1","article-title":"Opioid prescribing behaviors - prescription behavior surveillance system, 11 states, 2010-2016.","volume":"69","author":"Strickler","year":"2020","journal-title":"MMWR Surveill Summ"},{"key":"R57-20250801","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.amepre.2017.06.009","article-title":"Geographic variation in opioid and heroin involved drug poisoning mortality rates.","volume":"53","author":"Ruhm","year":"2017","journal-title":"Am J Prev Med"}],"container-title":["Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/EDE.0000000000001609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T15:03:07Z","timestamp":1754060587000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/EDE.0000000000001609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ede.0000000000001609","relation":{},"ISSN":["1044-3983"],"issn-type":[{"value":"1044-3983","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,16]]}}}